$PIII

P3 Health Partners Inc. (PIII): Results of Operations and Financial Condition

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 piii-20260810xexx991.htm EX-99.1 Document Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 H

Original reporting
Published Aug 10, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$PIII
Bullish
high confidence
Mentioned
$PIII
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PIIIBullishHigh
01

Why it matters

Q2 showed a swing to positive net income and a large improvement in adjusted EBITDA versus the prior-year quarter, prompting management to raise full-year adjusted EBITDA guidance.

02

Market read

Traders can update models immediately using the revised 2026 adjusted EBITDA range and the reported Q2 profitability metrics, with the call at 4:30 PM ET as a near-term catalyst.

03

What to watch

At-risk membership declined 10% YoY to ~105,000, which could offset margin gains if payer rationalization continues or if rate progression slows.

Relevance 7/10Novelty 9/10Timing: after-hours disclosure filed Aug 10, 2026, ahead of 4:30 PM ET conference call

Background

P3 Health Partners is a population health management company reporting quarterly results and providing revised full-year non-GAAP guidance.

Company-level read

Ticker impact

$PIIIBullishHigh confidence
Context

P3 reported Q2 2026 results and raised full-year 2026 adjusted EBITDA guidance to $80 million to $110 million.

Expected impact

Likely positive near-term bias as traders price the raised adjusted EBITDA range and improved medical margin/EBITDA trajectory.

Evidence & confidence

The filing includes specific Q2 adjusted EBITDA of $54.4 million and a revised full-year adjusted EBITDA range ($80m to $110m), both time-sensitive and directly tied to management’s outlook.

Market effects

Reinforces investor appetite for value-based population health operators showing contract and network execution improvements.

No specific regional spillover beyond US healthcare services.

Limited, company-specific US healthcare services update.

Counterpoint

Adjusted EBITDA and medical margin include favorable payer settlements and prior-year development, so the quality and sustainability of the improvement may be questioned.

Key entities

  • P3 Health Partners Inc.

    NASDAQ-listed population health management company filing an 8-K with Q2 results and revised 2026 adjusted EBITDA guidance.

  • Dr. Aric Coffman

    CEO quoted stating Q2 execution supports raising full-year 2026 adjusted EBITDA outlook.

Related articles

$PIIIMedAI 8/10

Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3%

P3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

$APEIMed

AMERICAN PUBLIC EDUCATION INC (APEI): Results of Operations and Financial Condition

AMERICAN PUBLIC EDUCATION INC (APEI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622572d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 American Public Education Reports Second Quarter 2026 Financial Results ~ Completed Institutional Combination Subsequent to Quarter End, Creating a Single HLC-Accredited Institution ~ ~ Raises Full Year 2026 Revenue, Net

$NKTXMed

Nkarta, Inc. (NKTX): Results of Operations and Financial Condition

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nktx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle) • Initia

$TELAMed

TELA Bio, Inc. (TELA): Results of Operations and Financial Condition

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622768d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction